Drug Trial Radar · NCT06754384
Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
552
Actual
Start
Jan 15, 2025
Primary completion
Dec 30, 2025
Study completion Feb 10, 2026
Sponsor
- Lead sponsor
- Sinovac Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The trial aims to assess the tolerability, safety, and immunogenicity of the tetravalent inactivated enterovirus vaccine in adults and children aged 6 months to 12 years. The main questions it aims to answer are: * Phase Ⅰ: The safety of the investigational vaccine in the target population based on adverse events (AEs); * Phase Ⅱ: The immunogenicity of the investigational vaccine in the target population. In Phase I, researchers will compare the safety of the investigational vaccine at low, medium, and high doses with the control vaccine; in Phase II, they will compare the safety and immunogenicity (including immune persistence) of the investigational vaccine at medium and high doses with the control vaccine. Procedure: * In Phase I, will be vaccinated with the investigational vaccine (at low, medium, and high doses) or the control EV71 vaccine/placebo in a 3:1 ratio, following a vaccination schedule of 0 and 1 month. Within each age group, and under the premise of ensuring safety, a dose-escalation trial will be conducted in reverse order of age. * In Phase II, participants in each age group will be randomly assigned to the medium-dose, high-dose investigational vaccine groups, and the control group in a 1:1:1 ratio, receiving two doses of the investigational vaccine or the EV71 vaccine (for ages 6-71 months)/placebo (for ages 6-12 years), with a one-month interval between the two doses. * For all participants in both Phase I and Phase II, immediate reactions within 30 minutes after each dose will be observed. Diary cards/contact cards will be used to collect solicited local and systemic adverse events (AEs) for 0-7 days and unsolicited AEs for 0-30 days after vaccination. Additionally, serious adverse events (SAEs) will be monitored from the start of vaccination until 6 months post-completion of the vaccination schedule. Furthermore, for participants of reproductive age in Phase I, pregnancy events will be collected.
Conditions
- Hand, Foot, and Mouth Disease (HFMD)
- Herpangina
Interventions
Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)Biological
Low-dose tetravalent inactivated enterovirus vaccine (Vero cell) )(only for phase Ⅰ)
Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)Biological
Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)
High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )Biological
High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months)Biological
EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months)
placebo (for ages 6-12 years)Biological
placebo (for ages 6-12 years)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ⅰ:The safety of the investigational vaccine in the target population based on AR.Time frame: 60 days
- Phase Ⅱ:Evaluate the seropositive conversion rates of the investigational vaccine in the target population.Time frame: 60 days
- Phase Ⅱ:Evaluate the geometric mean titer (GMT) of the investigational vaccine in the target population.Time frame: 60 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Provincial Center for Disease Control and Prevention
Hangzhou, Hangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.